Our Work
Latham & Watkins Advises NVentures on Investment in Evozyne
September 27, 2023
The firm represented NVIDIA’s venture capital arm on its investment in the AI-powered drug discovery platform.
Evozyne has announced the closing of an US$81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. Fidelity Management & Research Company and OrbiMed led the funding with participation from NVentures, NVIDIA’s venture capital arm. Previous investors Paragon Biosciences and Valor Equity Partners expanded their support in the round.
Latham & Watkins LLP represented NVentures in the funding round with a corporate deal team led by Bay Area partner Saad Khanani, with associate Chris Pham.